Zalifrelimab

DRUG6 trials

Sponsors

Agenus Inc., University of Colorado, Denver, Nelum Corp, Ann & Robert H Lurie Children's Hospital of Chicago, ImmunoGenesis

Conditions

Advanced Soft Tissue SarcomaAdvanced Solid CancersAdvanced Solid Cancers Refractory to PD-1 and PD-L1 TherapiesCancerDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic Cancer

Phase 1

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

CompletedNCT02694822

Agenus Inc.Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies

Start: 2016-04-30End: 2022-03-31Updated: 2025-03-17

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Active, not recruitingNCT04827953

Nelum CorpPancreatic Ductal Adenocarcinoma

Start: 2021-09-01End: 2025-04-30Updated: 2024-12-30

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

RecruitingNCT04943848

Ann & Robert H Lurie Children's Hospital of ChicagoDiffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant

Start: 2022-01-10End: 2027-09-01Target: 36Updated: 2026-03-17

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

RecruitingNCT06782555

ImmunoGenesisMetastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Metastatic Prostate Cancer

Start: 2025-01-08End: 2028-01-31Target: 71Updated: 2025-01-21

Phase 2

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Active, not recruitingNCT04028063

University of Colorado, DenverAdvanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma

Start: 2020-01-28End: 2027-12-31Target: 65Updated: 2026-04-20

Unknown Phase

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Agenus Inc.Cancer

Updated: 2026-05-06

Related Papers

Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line combination therapy in a Phase 1b/2 study in PDAC: NUMANTIA trial

2025-12-15

A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti–CTLA-4 Antibody) and Balstilimab (Anti–PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas

Clinical Cancer Research2025-05-161 citations

DIPG-32. NEOANTIGEN HEAT SHOCK PROTEIN VACCINE, RHSC-DIPGVAX, IS ASSOCIATED WITH INCREASED VACCINE-INDUCED B CELLS AND BCR/TCR REPERTOIRE DIVERSITY IN PEDIATRIC PATIENTS WITH DIFFUSE MIDLINE GLIOMAS

Neuro-Oncology2024-06-181 citations

DIPG-92. IMMUNE ACTIVATION STUDIES WITH THE NEOANTIGEN-BASED PEPTIDE VACCINE RHSC-DIPGVAX DEMONSTRATE ANTIBODY-MEDIATED RESPONSES AND EPITOPE SPREADING IN PEDIATRIC PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPG)

Neuro-Oncology2024-06-18

A single-arm, open-label phase 2 trial of doxorubicin plus zalifrelimab, a CTLA-4 inhibitor, with balstilimab, a PD-1 inhibitor, in patients with advanced/metastatic soft tissue sarcomas.

Journal of Clinical Oncology2023-06-019 citations

Treatment with doxorubicin and PD-1/CTLA-4 blockade improves T cell activation and anti-tumor efficacy in MCA-205 murine fibrosarcoma

The Journal of Immunology2023-05-012 citations

Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.

2022-11-24186 citations

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Journal of Clinical Oncology2021-12-21169 citations

Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.

2019-08-08133 citations

Angiosarcoma treated with checkpoint inhibitors: A single-institution experience.

Journal of Clinical Oncology2019-05-20

Phase I, open-label ascending dose trial of anti–CTLA-4 monoclonal antibody AGEN1884 in advanced solid malignancies, with expansion to patients refractory to recent anti–PD-1/PD-L1 therapy

Annals of Oncology2018-10-012 citations

Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.

Journal of Clinical Oncology2018-05-202 citations

Abstract 3654: AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model

Cancer Research2017-07-01

Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.

Journal of Clinical Oncology2017-05-201 citations